Summit Therapeutics Inc

0.00 (0.00%)
Earnings Announcements

Summit Therapeutics Reports Q2 Loss Per Share Of $0.23

Published: 09/29/2020 13:59 GMT
Summit Therapeutics plc (SMMT) - Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020.
Summit Therapeutics - Existing Cash & Cash Equivalents to Be Sufficient to Enable to Fund Operating Expenses,capex Requirements Through Jan 31, 2021.
Summit Therapeutics Inc Qtrly Diluted Loss per Share $0.23.
Revenue is expected to be $4.08 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $3.95 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.